ArticleInternational journal of clinical and experimental pathology2018
Improved radioiodine-131 imaging of prostatic carcinoma using the sodium iodide symporter gene under control of the survivin promoter.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- The effect of sodium iodide symporter protein on ablation success in patients with differentiated thyroid cancer.Annals of nuclear medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Improvement of radioiodine accumulation in non-thyroidal tumors by transfecting the sodium iodide symporter (NIS) gene has been successfully investigated in many studies. However, regarding the uncertain iodine influx and efflux efficiencies in different cells, the optimal imaging time by radioiodine following NIS gene transport remains unclear. This study aimed to investigate the serial expression of NIS under control of survivin promoter in prostate cancer PC-3 cells and xenografts by adenoviral vector (Ad-Sur-NIS), and determine the optimal imaging time for radioiodine application. In vitro, the
Indexed as
Identifiers
31949797PMC6962784W3026443997What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.